Compound ID | 68
Class: Bacteriophage
| Spectrum of activity: | Gram-negative |
| Details of activity: | SASPject™ PT1.2 targets Staphylococcus aureus, including MRSA. |
| Propensity to select resistant mutants: | Yes |
| Institute where first reported: | Phico Therapeutics Ltd., UK |
| Year first mentioned: | 2014 |
| Highest developmental phase: | Phase 1 |
| Development status: | Active |
| External links: | |
| Citation: | http://www.phicotx.co.uk/#products |